Sec Form 13D Filing - DOERR L JOHN filing for AMYRIS INC. (AMRS) - 2019-07-18

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13D

(Amendment No. 2)*

AMYRIS, INC.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

03236M200

(CUSIP Number)

Barbara Hager

c/o Foris Ventures, LLC

751 Laurel Street #717

San Carlos, CA 94070

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

COPY TO:

Jon M. Novotny, Esq.

Heidi Mayon, Esq.

c/o Goodwin Procter LLP

Three Embarcadero Center

San Francisco, CA 94111

(415) 733-6000

April 15, 2019

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box   ☐

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

c/o Foris Ventures, LLC

751 Laurel Street #717

San Carlos, CA 94070

The principal business address of each of the Reporting Persons is:

c/o Foris Ventures, LLC

751 Laurel Street #717

San Carlos, CA 94070

Pursuant to the 2017 Purchase Agreement (as defined below), on May 11, 2017 (the “Closing”) FV purchased (i) 30,728.589 shares of Series B Preferred Stock, (ii) Cash Warrants to purchase of 4,877,386 shares of Common Stock and (iii) the Dilution Warrant (as defined below) for aggregate cash consideration of $30,728,589.

The purchase price for the shares of Series B Preferred Stock and Warrants (as defined below) was issued for the cancellation of $30,728,589 of existing indebtedness owed by the Company to FV.

Pursuant to the Warrant Exercise Agreement (as defined below), on August 17, 2018, FV (i) exercised its Cash Warrant in full to purchase 4,877,386 shares of Common Stock for $21,460,498.40, (ii) surrendered its Dilution Warrant to the Company for cancellation after exercising it in full to purchase 2,106,217 shares of Common Stock for $3,159.33 and (iii) simultaneously acquired the New Warrant (as defined below) to purchase 4,877,386 shares of Common Stock in exchange for FV exercising the Cash Warrant for cash and surrendering the Dilution Warrant for cancellation. FV used working capital to exercise the Dilution Warrant and the proceeds of the Underwritten Offering (as defined below) were used to exercise the Cash Warrant.

Pursuant to the First 2019 Purchase Agreement (as defined below), on April 16, 2019, FV purchased (i) 6,732,369 shares of Common Stock and (ii) a warrant to purchase 5,424,804 shares of Common Stock for an aggregate purchase price of $20,000,000.

Pursuant to the Second 2019 Purchase Agreement (as defined below), on April 26, 2019, FV purchased (i) 2,832,440 shares of Common Stock and (ii) a warrant to purchase 3,983,230 shares of Common Stock for an aggregate purchase price of $14,999,996.55.

Pursuant to the 2019 Exchange Agreement (as defined below), on May 14, 2019, FV purchased (i) 1,122,460 shares of Common Stock and (ii) a warrant to purchase 352,638 shares of Common Stock for an aggregate purchase price of $5,162,500.

L. John Doerr’s individual holdings and holdings of entities affiliated with him (not including FV) resulted from equity compensation grants made to him in his capacity as a director of the Company and from private placements, respectively.

2017 Securities Purchase Agreement

On May 8, 2017, the Company, FV and certain other investors entered into a Securities Purchase Agreement (the “2017 Purchase Agreement”), for the issuance and sale of shares of the Company’s Series A 17.38% Convertible Preferred Stock (the “ Series A Preferred Stock”), shares of the Company’s Series B 17.38% Convertible Preferred Stock, (the “Series B Preferred Stock”), two series of warrants to purchase shares of the Company’s Common Stock at exercise prices of $7.80 per share and $9.30 per share (the “Cash Warrants”), and warrants to purchase additional shares of Common Stock in the event the Company undertakes certain dilutive transactions (the “Dilution Warrant” and, together with the Cash Warrants, the “Warrants”).

On July 7, 2017, the Company’s stockholders approved (the “Stockholder Approval”) the issuance of shares of Common Stock upon the conversion or exercise of the Series B Preferred Stock and Warrants sold pursuant to the 2017 Purchase Agreement. Following the Stockholder Approval, each share of Series B Preferred Stock automatically converted, without any further action by the holder, subject to the 2017 Beneficial Ownership Limitation (as defined below), on October 9, 2017. Also following the Stockholder Approval, the Cash Warrants became immediately exercisable. Notwithstanding the foregoing, pursuant to the 2017 Purchase Agreement, the holders of Series B Preferred Stock and Warrants did not receive Common Stock exceeding an amount such that the holder, together with its affiliates, would beneficially own in excess of 4.99% (or such other percentage as determined by the holder and notified to the Company in writing, not to exceed 9.99%, provided that any increase of such percentage will not be effective until 61 days after notice thereof) of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon conversion of such Series B Preferred Stock (the “2017 Beneficial Ownership Limitation”).

On October 18, 2017, FV notified the Company of its decision to increase the 2017 Beneficial Ownership Limitation to 9.99%.

The Dilution Warrant held by FV provided FV with the right to purchase a number of shares of Common Stock, at a price of $0.0015 per share, sufficient to provide it with full-ratchet anti-dilution protection for any issuance by the Company of equity or equity-linked securities during the three year period following the Closing (the “Dilution Period”) at a per share price (including any conversion or exercise price, if applicable) less than $6.30 per share.

Registration Rights

Pursuant to the 2017 Purchase Agreement, within 30 calendar days of the date of the Stockholder Approval, the Company has agreed to file a registration statement on Form S-3 (or other appropriate form if the Company is not then S-3 eligible) providing for the resale of the shares of Common Stock issuable upon conversion or exercise of the Series B Preferred Stock and Cash Warrants. The Company has agreed to use commercially reasonable efforts to cause such registration statement to become effective within 181 days following the Closing and commercially reasonable efforts to keep such registration statement effective at all times until (i) no party to the 2017 Purchase Agreement owns any shares of Common Stock issuable upon conversion or exercise of the Series B Preferred Stock and Warrants or (ii) the shares of Common Stock issuable upon conversion or exercise of the Series B Preferred Stock and Warrants are eligible for resale under Rule 144 without regard to volume limitations.

Warrant Transaction

After giving effect to certain dilutive issuances of equity and equity-linked securities by the Company in August 2017, the Cash Warrant held by FV was exercisable for 4,877,386 shares at an exercise price of $4.40 per share and the Dilution Warrant held by FV was exercisable for 2,106,217 shares at an exercise price of $0.0015 per share, in each case as of August 17, 2018 and subject to the 2017 Beneficial Ownership Limitation. The exercise price of the Cash Warrant held by FV was subject to standard adjustments as well as full-ratchet anti-dilution protection for any issuance by the Company of equity or equity-linked securities during the Dilution Period at a per share price less than the then-current exercise price of the Cash Warrant, subject to certain exceptions. Similarly, the Dilution Warrant provided FV with the right to purchase a number of shares of Common Stock, at a price of $0.0015 per share, sufficient to provide it with full-ratchet anti-dilution protection for any issuance by the Company of equity or equity-linked securities during the Dilution Period at a per share price (including any conversion or exercise price, if applicable) less than $6.30 per share. The Cash Warrant and Dilution Warrant each expired in July 2020.

On August 17, 2018, FV entered into that certain Warrant Exercise Agreement (the “Warrant Exercise Agreement”) with the Company pursuant to which FV (i) exercised its Cash Warrant in full to purchase 4,877,386 shares of Common Stock for $21,460,498.40, (ii) surrendered its Dilution Warrant to the Company for cancellation after exercising it in full to purchase 2,106,217 shares of Common Stock for $3,159.33 and (iii) simultaneously acquired a new warrant (the “New Warrant”) to purchase 4,877,386 shares of Common Stock at $7.52 per share in exchange for FV exercising the Cash Warrant and surrendering the Dilution Warrant for cancellation. The New Warrant has substantially identical terms to the Cash Warrant, except that (A) the expiration date of the New Warrant is fifteen months after issuance, (B) the New Warrant does not contain any anti-dilution protection, other than standard adjustments in the event of any dividends or distributions on the Company’s common stock, or any stock split, reverse stock split, recapitalization, reorganization or similar transaction, (C) the New Warrant only permits exercise after the six-month anniversary of issuance, and only permits “cashless” or “net” exercise after the twelve-month anniversary of issuance to the extent that there is not an effective registration statement covering the resale of the shares of Common Stock underlying the New Warrant, (D) the exercise price of the New Warrant is $7.52, subject to adjustment and (E) the exercise of the New Warrant is not be subject to the 2017 Beneficial Ownership Limitation. On July 10, 2019, the exercise price of the New Warrant was amended from $7.52 per share to $2.87 per share.

In connection with the Warrant Exercise Agreement, FV and the Company amended the Cash Warrant and the Dilution Warrant (but not Series B Preferred Stock) to remove the 2017 Beneficial Ownership Limitation. In addition to eliminating FV’s full-ratchet anti-dilution protection under the Cash Warrant and Dilution Warrant and the removal of the 2017 Beneficial Ownership Limitation in the warrants, the transactions contemplated by the Warrant Exercise Agreement resulted in the Company receiving proceeds of approximately $21.5 million from the exercise of FV’s Cash Warrant and Dilution Warrant.

Concurrently with the transactions contemplated by the Warrant Exercise Agreement, FV, the Company, another selling stockholder and B. Riley FBR, Inc. (the “Underwriter”) entered into that certain Underwriting Agreement dated as of August 17, 2017 (the “Underwriting Agreement”) relating to the sale of 7,654,148 shares of Common Stock. Under the terms of the Underwriting Agreement, FV sold all 4,877,386 shares of Common Stock issuable upon exercise of the Cash Warrant to the Underwriter at approximately $6.22 per share, with the Underwriter offering the shares to the public at $6.25 per share (the “Underwritten Offering”). In connection with the Underwritten Offering, FV agreed with the Underwriter, subject to certain exceptions, not to dispose of or hedge any of their Common Stock or securities convertible or exchangeable for shares of Common Stock during the 180 day period following the final prospectus supplement used in the Underwritten Offering (the “Lock-Up Agreement”). With respect to the FV shares, the Underwritten Offering was made pursuant to effective registration statement on Form S-3 (File No. 333-219732) initially filed by the Company with the SEC on August 4, 2017, including the prospectus contained therein, and prospectus supplement to such prospectus, dated August 17, 2018.

2019 FV Investments

On April 15, 2019, the Company entered into a Securities Purchase Agreement (the “First 2019 Purchase Agreement”) with FV, pursuant to which the Company agreed to sell and issue to FV 6,732,369 shares of Common Stock at a price of $2.87 per share, the closing bid price of the Common Stock on the Nasdaq Global Select Market on the trading day immediately prior to the date of execution of the First 2019 Purchase Agreement, as well as a warrant to purchase 5,424,804 shares of Common Stock at an exercise price of $2.87 per share, with an exercise term of two years from issuance, for aggregate proceeds to the Company of $20.0 million (the “First 2019 FV Investment”). The First 2019 Purchase Agreement includes customary representations, warranties and covenants of the parties and provides that the Company shall not effect any conversion of any Company security, and FV shall not have the right to exercise or convert any portion of any Company security, to the extent that, after giving effect to such issuance after exercise or conversion, FV, together with its affiliates, would beneficially own in excess of 19.99% of the number of shares of Common Stock outstanding (the “2019 Beneficial Ownership Limitation”).

The exercise price of the warrant is subject to standard adjustments but does not contain any anti-dilution protection, and the warrant only permits “cashless” or “net” exercise after the six-month anniversary of issuance, and only to the extent that there is not an effective registration statement covering the resale of the shares of Common Stock underlying the warrant. The closing of the First 2019 FV Investment occurred on April 16, 2019.

On April 24, 2019, the Company entered into a Securities Purchase Agreement (the “Second 2019 Purchase Agreement”) with FV, pursuant to which the Company agreed to sell and issue to FV 2,832,440 shares of Common Stock at a price of $5.12 per share, the closing bid price of the Common Stock on the Nasdaq Global Select Market on the trading day immediately prior to the date of execution of the Second 2019 Purchase Agreement, as well as a warrant to purchase 3,983,230 shares of Common Stock at an exercise price of $5.12 per share, with an exercise term of two years from the date of the initial exercise, for aggregate proceeds to the Company of approximately $15.0 million (the “Second 2019 FV Investment”). The Second 2019 Purchase Agreement includes customary representations, warranties and covenants of the parties and provides that the convertible securities held by FV and its affiliates are subject to the 2019 Beneficial Ownership Limitation. The exercise price of the warrant is subject to standard adjustments but does not contain any anti-dilution protection, and the warrant only permits “cashless” or “net” exercise after the six-month anniversary of issuance, and only to the extent that there is not an effective registration statement covering the resale of the shares of Common Stock underlying the warrant. The closing of the Second 2019 FV Investment occurred on April 26, 2019.

On May 10, 2019, the Company entered into an Exchange Agreement (the “2019 Exchange Agreement”) with FV, pursuant to which the Company agreed to sell and issue to FV 1,122,460 shares of Common Stock at a price of $4.60 per share, as well as a warrant to purchase 352,638 shares of Common Stock at an exercise price of $4.56 per share, the closing price of the Common Stock on the Nasdaq Global Select Market on the trading day immediately prior to the date of execution of the 2019 Exchange Agreement, with an exercise term of two years from the date of issuance, in exchange for the cancellation of a principal amount of debt equal to $5.0 million plus accrued interest (the “2019 Exchange”). The 2019 Exchange Agreement includes customary representations, warranties and covenants of the parties. The exercise price of the warrant is subject to standard adjustments but does not contain any anti-dilution protection, and the warrant only permits “cashless” or “net” exercise after the six-month anniversary of exercisability, and only to the extent that there is not an effective registration statement covering the resale of the shares of Common Stock underlying the warrant. In addition, the exercisability of the warrant is subject to stockholder approval in accordance with the rules and regulations of the Nasdaq Stock Market, which the Company intends to seek at its 2019 annual meeting of stockholders. The closing of the 2019 Exchange occurred on May 14, 2019.

General

The Reporting Persons acquired the securities described in this Schedule for investment purposes and they intend to review their investments in the Company on a continuing basis. Any actions the Reporting Persons might undertake will be dependent upon the Reporting Persons’ review of numerous factors, including, but not limited to: an ongoing evaluation of the Company’s business, financial condition, operations and prospects; price levels of the Company’s securities; general market, industry and economic conditions; the relative attractiveness of alternative business and investment o pportunities; and other future developments.

Subject to the limitations in the 2017 Purchase Agreement, the Reporting Persons may, at any time and from time to time, acquire additional securities of the Company, or retain or sell all or a portion of the securities then held, in the open market or in privately negotiated transactions. In addition, subject to the limitations in the 2017 Purchase Agreement, the Reporting Persons in discussions with management, the Board, and shareholders of the Company and other relevant parties or encourage such persons to consider or explore extraordinary corporate transactions, such as: a merger; sales or acquisitions of assets or businesses; changes to the capitalization or dividend policy of the Company; or other material changes to the Company’s business or corporate structure, including changes in management or the composition of the Board.

Other than as described above, none of the Reporting Persons currently has any plans or proposals that relate to, or would result in, any of the matters listed in Items 4(a)–(j) of Schedule 13D, although, depending on the factors discussed herein, the Reporting Persons may change their purpose or formulate different plans or proposals with respect thereto at any time.

(a)-(b)

The following sets forth, as of the date of this Statement, the aggregate number of shares of Common Stock and percentage of Common Stock beneficially owned by each of the Reporting Persons, as well as the number of shares of Common Stock as to which each Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition of, or shared power to dispose or to direct the disposition of, as of the date hereof, based on a total of 91,486,380 shares of Common Stock, which amount consists of (i) 90,726,226 shares of Common Stock issued and outstanding as of April 19, 2019 based on information provided to the Reporting Persons by the Company, and (ii) 3,495,157 shares of Common Stock issued or issuable to FV upon conversion or exercise of securities convertible into or exercisable for Common Stock within 60 days of July 18, 2019. For the purposes of calculating L. John Doerr’s beneficial ownership only, the percent of class set forth below is based on a total of 91,486,380 shares of Common Stock, which amount consists of (i) 90,726,226 shares of Common Stock issued and outstanding as of April 19, 2019 based on information provided to the Reporting Persons by the Company, (ii) 3,495,157 shares of Common Stock issued or issuable to FV upon conversion or exercise of securities convertible into or exercisable for Common Stock within 60 days of July 18, 2019, and (iii) 6,799 shares of Common Stock issuable to L. John Doerr upon the exercise of stock options exercisable for Common Stock within 60 days of July 18, 2019.

The securities reported herein consist of (i) 17,527,973 shares of Common Stock currently outstanding and held by FV, (ii) 3,495,157 shares of Common Stock issuable to FV upon exercise of certain other warrants held within 60 days of July 18, 2019, (iii) 567 shares of Common Stock held by VVT, (iv) 15,797 shares of Common Stock held by L. John Doerr or issuable to L. John Doerr upon exercise of options within 60 days of July 18, 2019, (v) 9,648 shares of Common Stock held by Clarus, LLC, (vi) 248,304 shares of Common Stock held by Kleiner Perkins Caufield & Byers XII, LLC and (vii) 4,531 shares of Common Stock held by KPCB XII Founders Fund, LLC.

10

The information set forth under Items 3, 4 and 5 and the agreements set forth on the Exhibits attached hereto ar e incorporated herein by reference. Other than the 2017 Purchase Agreement, Warrant Exercise Agreement, New Warrant and Lock-Up Agreement, First 2019 Purchase Agreement and Second 2019 Purchase Agreement described above, to the best of the knowledge of the Reporting Persons, there are no contracts, arrangements, understandings or relationships (legal or otherwise) between each Reporting Person and any person, with respect to the securities of the Company, including, but not limited to, transfer or voting of any of the securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies, including any securities pledged or otherwise subject to a contingency the occurrence of which would give another person voting power or investment power over such securities other than standard default and similar provisions contained in loan agreements.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: July 18, 2019